CD274 and non-small cell lung carcinoma: In advanced or metastatic NSCLC, the combination of immunotherapy and RT significantly improves 1- and 3-year overall survival; as well as progression-free survival, though but is also beneficial in adenocarcinomas and PD-L1-negative patients [158].